The US regulator has granted accelerated approval to anti-amyloid therapy Leqembi (lecanemab) with a fairly broad label to treat patients in the mild cognitive impairment or mild dementia stage of ...

Vaccinex went public in 2018, raising around $40m to advance its pipeline of neurodegenerative disease therapies. The initial ...

In its six-month financial report for the current fiscal year published this morning, the Japanese drugmaker revealed Leqembi (lecanemab) sales came in at JPY 16.3 billion (around $107 million ...

Treatment with donanemab (Kisunla) raised the risk of amyloid-related imaging abnormalities (ARIA) in people with early ...

Sales of Biogen’s BIIB key multiple sclerosis (“MS”) drugs like Tecfidera and Tysabri and spinal muscular atrophy (SMA) treatment, Spinraza, are being hurt due to competitive pressure, which is ...

Eisai and Biogen’s Leqembi (lecanemab) and Eli Lilly’s Kisunla (donanemab) dominate the landscape, winning approvals in the US in 2023 and 2024 respectively. Leqembi is forecast to see $5.3bn ...

which also include lecanemab (Leqembi). The donanemab secondary analysis "largely reinforces some of the key observations in the donanemab clinical trials -- that careful patient selection and ...

for lecanemab-irmb (U.S. brand name: LEQEMBI®) subcutaneous autoinjector for weekly maintenance dosing after it was granted Fast Track designation by the FDA. L ...

Lecanemab, marketed as Leqembi, is one such antibody that has gained attention. Developed by Eisai and Biogen, it received accelerated approval from the U.S. Food and Drug Administration in January ...